Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004
Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001
Diagnostic value of linear combination of CYFRA 21-1 and carcinoembryonic antigen in malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004
Diagnostic utility of pleural CEA and CYFRA 21-1 for malignant pleural effusions Source: Eur Respir J 2003; 22: Suppl. 45, 60s Year: 2003
Importance of tumour markers CYFRA 21-1 and NSE serum concentration values in diagnosis and esteem of nonmicrocelullar lung cancer expansion Source: Eur Respir J 2005; 26: Suppl. 49, 325s Year: 2005
Evaluation of pleural fluid levels and pleural-serum ratio of the tumor markers CEA, CA 15,3, CA 19,9, CA 72,4, CA 125 and CYFRA 21,1 in the diagnosis of malignant pleural effusion Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
CEA, Cyfra 21.1 and NSE levels in malignant and benign pleural effusion Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002
Tumor markers (TM) CEA, CYFRA 21-1,MCA and NSE in pleural effusion(PE) at malignant mezothelioma and metastatic tumor of pleura Source: Eur Respir J 2002; 20: Suppl. 38, 439s Year: 2002
Diagnostic value of cryobiopsy in patients with interstitial lung diseases integrating bronchoalveolar lavage, radiologic and clinical data Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020
Comparative evaluation of the diagnostic value of serum tumor markers versus those identified in bronchial lavage fluid in patients with histologically confirmed bronchial carcinoma Source: Eur Respir J 2003; 22: Suppl. 45, 256s Year: 2003
Prognostic value of cytokeratin 19 in bronchoalveolar lavage (BAL) in patients with acute lung injury (ALI) Source: Eur Respir J 2002; 20: Suppl. 38, 599s Year: 2002
Tumour markers in bronchoalveolar lavage and its diagnostic contribution in lung cancer not visible through regular fibrobronchoscopy Source: Eur Respir J 2002; 20: Suppl. 38, 276s Year: 2002
Diagnostic value of tumor markers and cells population in bronchoalveolar lavage in lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 37s Year: 2003
Diagnostic value of total cell count in bronchoalveolar lavage fluid from patients with interstitial lung diseases Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009
Clinical evaluation of NSE, CYFRA 21-1, CEA and MCA at patients (pts.) with metastatic pleural effusion (PE) Source: Eur Respir J 2005; 26: Suppl. 49, 448s Year: 2005
The diagnostic value of bronchoalvolar lavage (BAL) in the diagnosis of peripheral lung cancer (PLC) Source: Eur Respir J 2003; 22: Suppl. 45, 253s Year: 2003
CCL20 level in bronchoalveolar lavage fluid is correlated with the levels of serum indications in patients with pulmonary sarcoidosis Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease Year: 2010
Biodynamic approach to pretreatment level of tumor marker CYFRA 21-1 in differential diagnosis of single pulmonary nodules Source: Annual Congress 2003 - Early lung cancer diagnosis Year: 2003
Chitotriosidase as a possible marker of sarcoidosis activity Source: Annual Congress 2005 - Progresses in granolomatous lung disease Year: 2005
The analysis of tryptase in serum and bronchoalveolar lavage of sarcoidosis patients Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008